Compound Detail
CHEMBL1908360
EVEROLIMUS 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C
Basic Information
| ChEMBL ID | CHEMBL1908360 |
| Name | EVEROLIMUS |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | HKVAMNSJSFKALM-GKUWKFKPSA-N |
| Therapeutic | ✓ Yes |
17
Targets
33
Activities
2
Assay Types
20
PK Parameters
20
Publications
15
Known Names
20
Indications
1
Mechanisms
Molecular Properties
958.2
MW (Da)
6.20
ALogP
14
HBA
3
HBD
204.7
PSA (Ų)
0.13
QED
3
Ro5 Violations
9
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 2009 |
| Availability | Prescription |
| Chirality | Single Enantiomer |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| FK506-binding protein 1A inhibitor | INHIBITOR | Peptidyl-prolyl cis-trans isomerase FKBP1A | ✓ | ✓ |
Indications
Angiomyolipoma Angiomyolipoma Astrocytoma Astrocytoma Astrocytoma Breast Neoplasms Breast Neoplasms Breast Neoplasms Carcinoma, Renal Cell Carcinoma, Renal Cell Carcinoma, Renal Cell Neoplasms Neoplasms Neuroendocrine Tumors Neuroendocrine Tumors Neuroendocrine Tumors Pancreatic Neoplasms Pancreatic Neoplasms Tuberous Sclerosis Tuberous Sclerosis
ATC Classification
L01EG02
everolimus
Level 1: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Level 2: ANTINEOPLASTIC AGENTS
L04AH02
everolimus
Level 1: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Level 2: IMMUNOSUPPRESSANTS
Drug Warnings
Black Box Warning
immune system toxicity
Black Box Warning
vascular toxicity
Black Box Warning
nephrotoxicity
Black Box Warning
carcinogenicity
Black Box Warning
infectious disease
Black Box Warning
neurotoxicity
Black Box Warning
musculoskeletal toxicity
Black Box Warning
cardiotoxicity
Activity Summary
IC50 32 meas. best 10.3
Kd 1 meas. best 8.7
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| mTORC1 CHEMBL4296661 | IC50 | 10.3 | 10.225 | 0.1 | 2 |
| Cortical neurone CHEMBL5314314 | IC50 | 9.82 | 9.82 | 0.1 | 1 |
| Serine/threonine-protein kinase mTOR CHEMBL2842 | IC50 | 8.8 | 7.8 | 1.6 | 6 |
| Serine/threonine-protein kinase mTOR CHEMBL2842 | Kd | 8.7 | 8.7 | 2.0 | 1 |
| Bile salt export pump CHEMBL6020 | IC50 | 5.7 | 5.7 | 2000.0 | 1 |
| SQ20B CHEMBL614939 | IC50 | 5.26 | 5.2 | 5500.0 | 2 |
| DU-145 CHEMBL613508 | IC50 | 5.1 | 5.1 | 8000.0 | 1 |
| NON-PROTEIN TARGET CHEMBL3879801 | IC50 | 5.06 | 4.99 | 8700.0 | 2 |
| ATP-binding cassette sub-family C member 2 CHEMBL5748 | IC50 | 4.95 | 4.95 | 11300.0 | 1 |
| HCT-116 CHEMBL394 | IC50 | 4.92 | 4.92 | 12000.0 | 1 |
| CAKI-1 CHEMBL614067 | IC50 | 4.85 | 4.85 | 14000.0 | 1 |
| HT-29 CHEMBL384 | IC50 | 4.82 | 4.82 | 15000.0 | 1 |
| OVCAR-3 CHEMBL614213 | IC50 | 4.8 | 4.8 | 16000.0 | 1 |
| HOP-62 CHEMBL614643 | IC50 | 4.72 | 4.72 | 19000.0 | 1 |
| COLO 205 CHEMBL614561 | IC50 | 4.7 | 4.7 | 20000.0 | 1 |
| ATP-binding cassette sub-family C member 3 CHEMBL5918 | IC50 | 4.08 | 4.08 | 84000.0 | 1 |
| ATP-binding cassette sub-family C member 4 CHEMBL1743128 | IC50 | 4.02 | 4.02 | 95000.0 | 1 |
| Voltage-gated potassium channel, IKs; KCNQ1(Kv7.1)/KCNE1(MinK) CHEMBL2221347 | IC50 | 4.0 | 4.0 | 100000.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| AUC | 0.561 | uM.hr | Homo sapiens |
| AUC | 33636.0 | ng.hr.mL-1 | Mus musculus |
| AUC | 42267.0 | ng.hr.mL-1 | Mus musculus |
| AUC | 804.0 | ng.hr.mL-1 | Mus musculus |
| AUC | 640.0 | ng.hr.mL-1 | Mus musculus |
| CL | 4.6 | mL.min-1.kg-1 | Mus musculus |
| CL | 3.75 | mL.min-1.kg-1 | Mus musculus |
| CL | 171.09 | mL.min-1.kg-1 | Mus musculus |
| Cmax | 3.464 | ug.mL-1 | Mus musculus |
| Cmax | 3.941 | ug.mL-1 | Mus musculus |
| Cmax | 0.057 | ug.mL-1 | Mus musculus |
| Cmax | 0.043 | ug.mL-1 | Mus musculus |
| F | 20.0 | % | Homo sapiens |
| T1/2 | 6.5 | hr | Mus musculus |
| T1/2 | 5.7 | hr | Mus musculus |
| T1/2 | 15.8 | hr | Mus musculus |
| Tmax | 0.5 | hr | Mus musculus |
| Tmax | 2.0 | hr | Mus musculus |
| Tmax | 24.0 | hr | Mus musculus |
| Tmax | 4.0 | hr | Mus musculus |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
Data from ChEMBL 36 via Core Engine